- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04834414
Gekoeld bloedplaatjesonderzoek "CHIPS" (CHIPS)
Gekoeld bloedplaatjesonderzoek
A phase 3 randomized partial blind storage duration ranging study in patients undergoing complex cardiac surgery that will compare the transfusion of cold stored platelets to standard room temperature stored platelets. The primary objective is to establish that cold stored platelets have a non-inferiority (or superiority) to room temperature platelets.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
Western Australia
-
Murdoch, Western Australia, Australië, 6150
- Fiona Stanley Hospital
-
Nedlands, Western Australia, Australië, 6009
- Sir Charles Gairdner Hospital
-
-
-
-
Arizona
-
Pheonix, Arizona, Verenigde Staten, 85054
- Mayo Clinic Arizona
-
Tuscon, Arizona, Verenigde Staten, 85713
- Banner University Medical Center
-
-
California
-
Los Angeles, California, Verenigde Staten, 90095
- Ronald Reagan UCLA Medical Center
-
-
Florida
-
Gainesville, Florida, Verenigde Staten, 32608
- University of Florida
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Northwestern Memorial Hospital
-
Maywood, Illinois, Verenigde Staten, 60153
- Loyola Universtiy Medical Center
-
-
Kansas
-
Kansas City, Kansas, Verenigde Staten, 66103
- University of Kansas Medical Center
-
-
Kentucky
-
Lexington, Kentucky, Verenigde Staten, 40536
- University of Kentucky
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- John Hopkins
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- University of Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55455
- University of Minnesota
-
Rochester, Minnesota, Verenigde Staten, 55905
- Mayo Clinic
-
-
North Carolina
-
Winston-Salem, North Carolina, Verenigde Staten, 27157
- Wake Forest
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45229
- Cincinnati Children's Hospital
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15232
- University of Pittsburgh Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, Verenigde Staten, 02910
- Rhode Island Hospital
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75235
- University of Texas Children's Medical Center
-
Dallas, Texas, Verenigde Staten, 75235
- University of Texas Medical Center Clements
-
Houston, Texas, Verenigde Staten, 77030
- Memorial Hermann Texas Medical Center
-
Houston, Texas, Verenigde Staten, 77030
- Baylor Texas Children's
-
-
Wisconsin
-
Madison, Wisconsin, Verenigde Staten, 53792
- University of Wisconsin- Madison
-
Milwaukee, Wisconsin, Verenigde Staten, 53226
- Children's Hospital of Wisconsin
-
Milwaukee, Wisconsin, Verenigde Staten, 53215
- Aurora St. Luke's Medical Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Viable neonates ≥ 3 kg at time of enrollment (as defined in Section 4.1) OR age greater than 28 days and less than 85 years of age at time of consent; AND
- Planned complex cardiac surgery with planned use of cardiopulmonary bypass, with an expectation of bleeding requiring platelet transfusion.
Exclusion Criteria:
- Expected order for washed or volume reduced platelets
- Patient with known anti-platelet antibodies
- Platelet transfusion refractoriness due to anti-HLA antibodies
- Known or suspected pregnancy
- Previously randomized in this study
- Conscious objection or unwillingness to receive blood products
- Known IgA deficiency
- Known congenital platelet disorder
- Known congenital bleeding disorder
- Planned post-operative extracorporeal membrane oxygenation (ECMO), ventricular assist device (VAD), and/or continuous renal replacement therapy (CRRT)/ hemodialysis
- Patients intended to receive whole blood either intra-operative or post-operative for bleeding
- Platelet transfusion (of any type) within 24 hours prior to the date of surgery
- Pre-operative thrombocytopenia, defined as platelet count <75x10(9)/L, based on the most recent labs completed within 72 hours prior to the date of surgery.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Room Temperature Platelets
Platelets stored at 20-24 degrees Celsius |
Platelets stored at 20-24 degrees Celsius |
|
Experimenteel: Cold Stored Platelets
Platelets stored at 1-6 degree Celsius |
Platelets stored at 1-6 degree Celsius |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Hemostatic Efficacy
Tijdsspanne: 24 hours after first study platelet transfusion
|
Assessed by a bleeding score, a modified Peri-Operative bleeding score: the score ranges from 1-5. A lower score signifies a better outcome. |
24 hours after first study platelet transfusion
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Chest Tube Output Through 24 Hours
Tijdsspanne: 24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)
|
Chest tube output will be assessed by volume |
24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Blood Product Administration
Tijdsspanne: 24 and 72 hours from start time of first study platelet transfusion
|
The quantity of RBCs, Plasma, Platelets, Cryoprecipitate, and Whole blood |
24 and 72 hours from start time of first study platelet transfusion
|
|
Transfusion Associated Adverse Events
Tijdsspanne: within 7 days of first study platelet transfusion
|
As per CDC guidelines for transfusion associated adverse events |
within 7 days of first study platelet transfusion
|
|
Arterial Thrombotic Event
Tijdsspanne: within 7 days of first study platelet transfusion
|
Stroke, MI, aortic thromboic even |
within 7 days of first study platelet transfusion
|
|
Venous Thrombotic Event
Tijdsspanne: within 7 days of first study platelet transfusion
|
Deep vein thrombosis or pulmonary embolism confirmed by ultrasound, venography, perfusion scan, spiral CT, MRI, or pulmonary angiogram |
within 7 days of first study platelet transfusion
|
|
All Cause Mortality
Tijdsspanne: up to 28 days
|
Death for any reason |
up to 28 days
|
|
Total Dose of Individual Hemostatic Adjuncts (Units/kg)
Tijdsspanne: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates |
24 and 72 hours from start time of first study platelet transfusion
|
|
Total Dose of Individual Hemostatic Adjuncts (mcg/kg)
Tijdsspanne: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates |
24 and 72 hours from start time of first study platelet transfusion
|
|
Total Dose of Individual Hemostatic Adjuncts (mg/kg)
Tijdsspanne: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates |
24 and 72 hours from start time of first study platelet transfusion
|
|
Total Dose of Individual Hemostatic Adjuncts (Grams/kg)
Tijdsspanne: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates Epsilon-amino-caproic acid |
24 and 72 hours from start time of first study platelet transfusion
|
|
Mechanical Ventilation
Tijdsspanne: up to 28 days after first study platelet transfusion
|
Number of participants with need for mechanical ventilation |
up to 28 days after first study platelet transfusion
|
|
Length of Stay
Tijdsspanne: up to 28 days
|
ICU and hospital length of stay |
up to 28 days
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hemoglobin
Tijdsspanne: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hematocrit
Tijdsspanne: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement). |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Platelet Count
Tijdsspanne: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- INR
Tijdsspanne: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- PTT
Tijdsspanne: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Fibrinogen
Tijdsspanne: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Unplanned Sternal Closure Delay
Tijdsspanne: prior to ICU admission
|
Sternum left open after cardiac surgery |
prior to ICU admission
|
|
Re-exploration for Bleeding
Tijdsspanne: 24 hours first study platelet transfusion
|
Return to OR after ICU admission |
24 hours first study platelet transfusion
|
|
Unplanned Extracorporeal Support Post Operatively
Tijdsspanne: within 48 hours of first study platelet transfusion
|
Unplanned placement on ECMO post operatively within 48 hours of 1st transfusion |
within 48 hours of first study platelet transfusion
|
|
Morbidities After ICU Admission
Tijdsspanne: within 7 days of first study platelet transfusion
|
Acute respiratory distress syndrome, need for and duration of renal support, renal failure, septic shock |
within 7 days of first study platelet transfusion
|
|
Measures of End Organ Injury- BUN and Creatinine
Tijdsspanne: within 48 hours of first study platelet transfusion worst value
|
If BUN, creatinine are collected clinically.- worst value |
within 48 hours of first study platelet transfusion worst value
|
|
Measures of End Organ Injury- Lactate
Tijdsspanne: within 48 hours of first study platelet transfusion worst value
|
If lactate was collected clinically. Worst value |
within 48 hours of first study platelet transfusion worst value
|
|
Measures of End Organ Injury- Troponin
Tijdsspanne: within 48 hours of first study platelet transfusion.
|
If lactate was collected clinically. Worst value |
within 48 hours of first study platelet transfusion.
|
|
Measures of End Organ Injury- ALT and AST
Tijdsspanne: within 48 hours of first study platelet transfusion.
|
If lactate was collected clinically. Worst value |
within 48 hours of first study platelet transfusion.
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: Philip C Spinella, MD, University of Pittsburgh
- Studie directeur: Marie E Steiner, MD, University of Minnesota
- Studie directeur: Nicole D Zantek, MD, University of Minnesota
Publicaties en nuttige links
Algemene publicaties
- Krachey E, Viele K, Spinella PC, Steiner ME, Zantek ND, Lewis RJ. The design of an adaptive clinical trial to evaluate the efficacy of platelets stored at low temperature in surgical patients. J Trauma Acute Care Surg. 2018 Jun;84(6S Suppl 1):S41-S46. doi: 10.1097/TA.0000000000001876.
- Strandenes G, Sivertsen J, Bjerkvig CK, Fosse TK, Cap AP, Del Junco DJ, Kristoffersen EK, Haaverstad R, Kvalheim V, Braathen H, Lunde THF, Hervig T, Hufthammer KO, Spinella PC, Apelseth TO. A Pilot Trial of Platelets Stored Cold versus at Room Temperature for Complex Cardiothoracic Surgery. Anesthesiology. 2020 Dec 1;133(6):1173-1183. doi: 10.1097/ALN.0000000000003550.
- Zantek ND, Steiner ME, VanBuren JM, Lewis RJ, Berry NS, Viele K, Krachey E, Dean JM, Nelson S, Spinella PC. Design and logistical considerations for the randomized adaptive non-inferiority storage-duration-ranging CHIlled Platelet Study. Clin Trials. 2023 Feb;20(1):36-46. doi: 10.1177/17407745221126423. Epub 2022 Dec 21.
- Spinella PC, Zantek ND, VanBuren JM, Nicolson SC, Khanna AK, Klompas AM, Boisen ML, Williams TM, Monteleone M, Bashir DA, Pavey W, Smith BB, Ahmed MI, Niebler RA, Jeng E, Flynn BC, Joshi RV, Preuss JF, Goswami D, Yamada C, Lewis C, Cohn CS, Tint H, Kwak J, Sodha N, Simon ER, Van PY, Greilich PE, Booth FVM, Carter CP, Keegan A, Cap AP, Matuk J, McGlothlin A, Berry NS, Lewis RJ, Steiner ME; CHIPS Investigator Group. Cold and Room-Temperature Platelets in Cardiac Surgery: The CHIPS Randomized Clinical Trial. JAMA. 2026 Aug 17. doi: 10.1001/jama.2026.13328. Online ahead of print.
- Lewis AR, Peffley N, Klompas AM, Ashrani AA. Role of individual factor X concentrate pharmacokinetic studies in perioperative management of AL amyloidosis-associated acquired factor X deficiency. Transfusion. 2023 Sep;63(9):1773-1777. doi: 10.1111/trf.17477. Epub 2023 Jul 10.
- Klompas AM, Stubbs J. Massive transfusion protocol: What's in a name? Transfusion. 2023 Apr;63(4):896-897. doi: 10.1111/trf.17297. No abstract available.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CHIPS
- W81XWH2090021 (Ander subsidie-/financieringsnummer: DoD)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .